International Textbook of Diabetes Mellitus, 4th Ed., Chapter 17 – Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals

References:

1. Chahil TJ, Ginsberg GN: Diabetic dyslipidemia. Endocrinology and Metabolism Clinics of North America 2006;35:491–510.
2. Laakso M, Sarlund H, Mykkanen L: Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 1990;10:223–231.
3. Howard BV, Mayer-Davis EJ, Goff D, et al.: Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Metabolism 1998;47:1174–1179.
4. Haffner SM, Mykkanen L, Festa A: Insulin-resistant subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975–980.
5. Goff DC, Jr, D'Agostino RB, Jr, Haffner SM, Otvos JD: Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 2005;54:264–270.
6. Howard BV, Cowan LD, Go O, et al.: Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. Diabetes Care 1998;21:1258–1265.
7. Ginsberg HN, Illingworth DR: Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes. American Journal of Cardiology 2001;88:9H–15H.
8. Rivellese AA, De Natale C, Di Marino L, et al.: Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. Journal of Clinical Endocrinology & Metabolism 2004;89:2153–2159.
9. Ginsberg HN, Jones J, Blaner WS, et al.: Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arteriosclerosis, Thrombosis, and Vascular Biology 1995;15:1829–1838.
10. Sharret AR, Chambless LE, Heiss G, et al.: Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. Arteriosclerosis, Thrombosis, and Vascular Biology 1995;15:2122–2129.
11. Syvanne M, Hilden H, Taskinen M-R: Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease. Journal of Lipid Research 1994;35:15–26.
12. Reyes-Soffer G, Holleran S, Karmally W, et al.: Measures of postprandial lipoproteins are not associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus. Journal of Lipid Research 2009;50:1901–1909.
13. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299–308.
14. Bansal S, Buring JE, Rifai N, et al.: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309–316.
15. Ginsberg HN: Lipoprotein physiology. Endocrinology and Metabolism Clinics of North America 1998;27:503–519.
16. Haidari M, Leung N, Mahbub F, et al.: Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. The Journal of Biological Chemistry 2002;277:31646–31655.
17. Hogue J-C, Lamarche B, Trembley AJ, et al.: Evidence of increased secretion of apolipoprotein B-48 containing lipoproteins in subjects with type 2 diabetes. Journal of Lipid Research 2007;48:1336–1342.

18. Xiao C, Bandsma RH, Dash S, et al.: Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arteriosclerosis, Thrombosis, and Vascular Biology 2012;32:1513–1519.
19. van Dijk KW, Rensen PC, Voshol PJ, Havekes LM: The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Current Opinion in Lipidology 2004;15:239–246.
20. Minicocci I, Santini S, Cantisani V, et al.: Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. Journal of Lipid Research 2013; 54:3481–3490.
21. Koster A, Chao YB, Mosior M, et al.: Transgenic angiopoietin-like (angptl) 4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 2005;146:4943–4950.
22. Cohn JS, Patterson BW, Uffelman KD, et al.: Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. Journal of Clinical Endocrinology & Metabolism 2004;89:3949–3955.
23. Nagashima K, Lopez C, Donovan D, et al.: Effects of the PPAR agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. Journal of Clinical Investigation 2005;115:1323–1332.
24. Graham MJ, Lee RG, Bell TA, III et al.: Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circulation Research 2013;112:1479–1490.
25. Chapman MJ, Ginsberg HN, Amarenco P, et al.: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 2011;32:1345–1361.
26. Ginsberg HN, Fisher EA: The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. Journal of Lipid Research 2009;(Suppl):S162–S166.
27. Moon BC, Hernandez-Ono A, Stiles B, et al.: Apolipoprotein B secretion is regulated by hepatic triglyceride, and not insulin, in a model of increased hepatic insulin signaling. Arteriosclerosis, Thrombosis, and Vascular Biology 2012;32:236–246.
28. Ginsberg HN, Zhang Y-L, Hernandez-Ono A: Regulation of plasma triglycerides in insulin resistance and diabetes. Archives of Medical Research 2005;36:232–240.
29. Avramoglu RK, Basciano H, Adeli K: Lipid and lipoprotein dysregulation in insulin resistant states. Clinica Chimica Acta 2006; 368:1–19.
30. Adiels M, Olofsson S-O, Taskinen M-R, Boren J: Diabetic dyslipidemia. Current Opinion in Lipidology 2006;17:238–246.
31. Ozcan U, Cao Q, Yilmaz E, et al.: Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457–461.
32. Ota T, Gayet C, Ginsberg HN: Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. Journal of Clinical Investigation 2008;118:316–332.
33. Choi SH, Ginsberg HN: Increased very low density lipoprotein secretion, hepatic steatosis, and insulin resistance. Trends in Endocrinology and Metabolism 2011;22(9):353–363.
34. Donnelly KL, Smith CI, Schwarzenberg SJ, et al.: Sources of fatty acids stored in liver and secreted via lipoprotein in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation 2005;115:1343–1151.
35. Ginsberg HN, Yu Y-H: Adipocyte signaling and lipid homeostasis. Sequelae of insulin-resistant adipose tissue. Circulation Research 2005;96:1042–1052.
36. Zhang Y-L, Hernandez-Ono A, Ko C, et al.: Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids 1: differential effects of delivering fatty acids via albumin or remnant-like emulsion particles. The Journal of Biological Chemistry 2004;279:19362–19374.

37. Lewis GF, Uffelman KD, Szeto LW, et al.: Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. Journal of Clinical Investigation 1995;95:158–166.
38. Lamming DW, Sabatini DM: A central role for mTOR in lipid homeostasis. Cell Metabolism 2013;18(4):465–469.
39. Zhang YL, Hernandez-Ono A, Siri P, et al.: Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. The Journal of Biological Chemistry 2006;281: 37603–37615.
40. Sharma V, Forte TM, Ryan RO: Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol. Current Opinion in Lipidology 2013;24:153–159.
41. Robciuc MR, Maranghi M, Lahikainen A, et al.: Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arteriosclerosis, Thrombosis, and Vascular Biology 2013;33:1706–1713.
42. Krauss RM, Siri PW: Metabolic abnormalities: triglyceride and low-density lipoprotein. Endocrinology and Metabolism Clinics of North America 2004;33:405–415.
43. Stampfer MJ, Krauss RM, Ma J, et al.: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882–888.
44. Williams PT, Zhao XQ, Marcovina SM, et al.: Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS). PLoS ONE 2013;8:e56782.
45. Timmins JM, Lee JY, Boudyguina E, et al.: Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-1. Journal of Clinical Investigation 2005;115:1333–1342.
46. Lewis GF, Radar DJ: New insights into the regulation of HDL. Metabolism and reverse cholesterol transport. Circulation Research 2005;96:1221–1232.
47. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
48. Baigent C, Blackwell L, Emberson J, et al.: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–1681.
49. Ginsberg HN: The 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol: Questions, Questions, Questions. Circulation Research 2014;114:761–764.
50. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110:227–239.
51. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. pp. 2363–2372.
52. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine 2005;352:1425–1435.
53. Cannon CP, Braunwald E, McCabe CH, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine 2004;350:1495–1504.
54. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–696.
55. Knopp RH, D'Emden M, Smilde JG, Pocock SJ: Efficacy and safety of atorvastatin in the prevention of cardiovascular endpoints in subjects with type 2 diabetes. Diabetes Care 2006;29:1478–1485.

56. Stone NJ, Robinson J, Lichtenstein AH, et al.: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2013. Published online before print November 12, 2013, doi:10.1161/01.cir.0000437738.63853.7a.
57. Grundy SM: Low-density lipoprotein, non-high density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002;106:2526–2529.
58. Pischon T, Girman CJ, Sacks FM: Non-high density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005;112:3375–3383.
59. Boden WE, Probstfield JL, Anderson T, et al.: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine 2011;365:2255–2267.
60. Ginsberg HN, Elam MB, Lovato LC, et al.: Effects of combination lipid therapy in type 2 diabetes mellitus. New England Journal of Medicine 2010;362:1563–1574.
61. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 2007;30:S4–S41.
62. Buse JB, Ginsberg HN, Bakris GL, et al.: Primary prevention of cardiovascular diseases in people with diabetes mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162–172.
63. Brunzell JD, Davidson M, Furberg CD, et al.: Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. Journal of the American College of Cardiology 2008;51:1512–1524.
64. Turner RC, Millns H, Neil HAW, et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823–828.
65. Robins SJ, Collins D,Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585–1591.
66. Tenenbaum A, Motro M, Fisman EZ, et al.: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Archives of Internal Medicine 2005; 165:1154–1160.
67. Robins SJ, Rubins HB, Faas FH, et al.: Insulin resistance and cardiovascular events with low HDL cholesterol. Diabetes Care 2003;26:1513–1517.
68. Guyton JR, Slee AE, Anderson T, et al.: Relationship of lipoproteins to cardiovascular events. The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology 2013;62(17):1580–1584.
69. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. Journal of Cardiovascular Risk 1996;3:213–219.
70. Di AE, Sarwar N, Perry P, et al.:Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993–2000.
71. Ballantyne CM, Olsson AG, Cook TJ, et al.: Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046–3051.
72. Scott R, O'Brien R, Fulcher G, et al.: Effects of fenofibrate treatment on cardiovascular disease risk in 9.795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493–498.
73. Mero N, Malmstrom R, Steiner G, et al.: Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000;150:167–177.

74. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002;346:393–403.
75. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine 2001;344:1343–1350.
76. The Look AHEAD Research Group: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 2007;30:1374–1383.
77. Wing RR, Bolin P, Brancati FL, et al.: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England Journal of Medicine 2013;369:145–154.
78. National Cholesterol Education Program(NCEP):Third Report of The National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421.
79. Ginsberg HN: Efficacy and mechanism of action of statins in the treatment of diabetic dyslipidemia. Journal of Clinical Endocrinology & Metabolism 2006;91:383–392.
80. Collins R, Armitage J, Parish S, et al., Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes. Lancet 2005;361:2005–2016.
81. Keech A, Colquhoun D, Best J, et al.: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003;26:2713–2721.
82. Haffner SM, Alexander CM, Cook TJ, for the Scandinavian Simvastatin Survival Study Group: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine 1999;159:2661–2667.
83. Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98:2513–2519.
84. Deedwania P, Barter P, Carmena R, for the Treating to New Targets Investigators: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets Study. Lancet 2006;368:919–928.
85. Sever PS, Poulter NR, Dahlof B, for the ASCOT Investigators: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes. Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOTT-LLA). Diabetes Care 2005;28:1151–1157.
86. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 2002;288:2998–3007.
87. Ridker PM, Danielson E, Fonseca FA, et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 2008;359:2195–2207.
88. Sattar N, Preiss D, Murray HM, et al.: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735–742.
89. Preiss D, Seshasai SR, Welsh P, et al.: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556–2564.
90. Waters DD, Ho JE, Boekholdt SM, et al.: Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. Journal of the American College of Cardiology 2013;61:148–152.
91. Karpe F, Frayn KN:The nicotinic acid receptor -- a new mechanism for an old drug. Lancet 2004;363:1892–1894.

92. Carlson LA: Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. Journal of Internal Medicine 2005; 258(2):94–114.
93. Ginsberg HN: Niacin in the metabolic syndrome: more risk than benefit? Nature Clinical Practice Endocrinology & Metabolism 2006;2(6):300–301.
94. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal 2013;34:1279–1291.
95. The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351–364.
96. Staels B, Kuipers F: Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007;67:1383–1392.
97. Zieve FJ, Kalin MF, Schwartz SI, et al.: Results of the glucose lowering effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clinical Therapeutics 2007;29:74–83.
98. Dujovne CA, Ettinger MP, McNeer JF: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. American Journal of Cardiology 2002;90:1092–1097.
99. Davidson MH, McGarry T, Bettis R, et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. Journal of the American College of Cardiology 2002;40:2125–2134.
100. Ballantyne CM, Houri J, Notarbartolo A, et al.: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409–2415.
101. Baigent C, Landray MJ, Reith C, et al.: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181–2192.
102. Staels B, Dallongeville J, Auwerx J, et al.: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088–2093.
103. Fruchart J-C, Brewer HB, Jr, Leitersdorf E: Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. American Journal of Cardiology 1998;81:912–917.
104. Rader DJ, Haffner SM: Role of fibrates in the management of hypertriglyceridemia. American Journal of Cardiology 1999;83: 30F–35F.
105. Frick MH, Elo MO, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New England Journal of Medicine 1987;317: 1237–1245.
106. Koskinen P, Manttari M, Manninen V, et al.: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820–825.
107. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. New England Journal of Medicine 1999; 341:410–418.
108. Rubins HB, Robins SJ, Collins D, et al., for the VA-HIT Study Group: Diabetes, plasma insulin, and cardiovascular disease. Archives of Internal Medicine 2002;162: 2597–2604.
109. Keech A, Simes RJ, Barter P: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849–1861.
110. Lincoff AM, Tardif JC, Neal B, et al.: Evaluation of the dual peroxisome proliferator-activated receptor alpha/gamma agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. American Heart Journal 2013;166: 429–434.